Author Archives: april@madhedgefundtrader.com

Not Bad For Scraps

Everyone forgets that Pfizer (PFE) tried to buy AstraZeneca (AZN) for scraps back in 2014. The UK Parliament threw a fit, the deal died, and Wall Street moved on. Fast forward, AstraZeneca is worth double what Pfizer is. The press still treats it like a mid-tier pharma shop. Meanwhile, it’s running the table in oncology. […]